Literature DB >> 26697193

c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases.

Mariana Fathy Gayyed1, Nehad M R Abd El-Maqsoud1, Amr Abd El-Hameed El-Heeny1, Mostafa Fuad Mohammed1.   

Abstract

BACKGROUND: c-MET plays an important role in tumor proliferation, invasion and metastasis. In this study we examined the expression of c-MET in colorectal adenomas, primary adenocarcinomas and their corresponding lymph node, peritoneal and liver metastases. We correlated our findings with clinicopathological features.
METHODS: Twenty three cases of colorectal adenoma and 102 cases of primary colorectal carcinoma and their corresponding metastases (44 lymph nodes, 21 peritoneal deposits and 16 liver metastases) were studied to evaluate c-MET expression by immunohistochemistry. For comparison, 12 sections of adjacent healthy colorectal mucosa were examined.
RESULTS: Statistically significant differences were present among normal tissues, colorectal adenomas and primary colorectal carcinomas (P=0.011). Normal tissues showed a negative or weak reaction in 66.67% and 33.33% of cases respectively. Expression of c-MET was positive in 47.8% of adenomas. A significant positive association was identified between c-MET high expression and degree of dysplasia (P=0.024). c-MET was highly expressed in 66.7% of primary colorectal carcinoma. Significant positive correlations were detected between c-MET expression and TNM stage (P=0.036), lymph node metastasis (LNM), peritoneal deposits and liver metastasis (P=0.038, P=0.094 and P=0.045, respectively). c-MET expression in metastatic tissues was significantly higher than that of the primary tumor.
CONCLUSIONS: c-MET expression is gradually up-regulated in the development and progression of colorectal cancer (CRC) from normal epithelium to adenoma to colorectal carcinoma to metastases.

Entities:  

Keywords:  c-MET; colorectal adenoma; immunohistochemistry; metastasis; primary colorectal carcinoma

Year:  2015        PMID: 26697193      PMCID: PMC4671852          DOI: 10.3978/j.issn.2078-6891.2015.072

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  49 in total

1.  c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma.

Authors:  A A Abou-Bakr; A Elbasmi
Journal:  Gulf J Oncolog       Date:  2013-07

2.  Chemotherapy and immunotherapy in metastatic colorectal cancer.

Authors:  Luigi Frati; Giovanni Codacci-Pisanelli
Journal:  N Engl J Med       Date:  2009-05-14       Impact factor: 91.245

3.  Fifty years of cancer incidence: CI5 I-IX.

Authors:  D Max Parkin; Jacques Ferlay; Maria-Paula Curado; Freddie Bray; Brenda Edwards; Hai-Rim Shin; David Forman
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

4.  Peritoneal elastic lamina invasion in colorectal cancer: the answer to a controversial area of pathology?

Authors:  Giacomo Puppa; Neil A Shepherd; Kieran Sheahan; Colin J R Stewart
Journal:  Am J Surg Pathol       Date:  2011-03       Impact factor: 6.394

5.  cMET and phospho-cMET protein levels in breast cancers and survival outcomes.

Authors:  Kanwal P Raghav; Wenting Wang; Shuying Liu; Mariana Chavez-MacGregor; Xiaolong Meng; Gabriel N Hortobagyi; Gordon B Mills; Funda Meric-Bernstam; George R Blumenschein; Ana M Gonzalez-Angulo
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

6.  c-Met expression in primary tumors and their corresponding distant metastases.

Authors:  Martin Isaksson-Mettävainio; Bethany Van Guelpen; Ake Oberg; Roger Stenling; Richard Palmqvist; Maria L Henriksson
Journal:  Mol Med Rep       Date:  2008 Nov-Dec       Impact factor: 2.952

Review 7.  Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.

Authors:  Lorenza Landi; Gabriele Minuti; Armida D'Incecco; Federico Cappuzzo
Journal:  Curr Opin Oncol       Date:  2013-03       Impact factor: 3.645

Review 8.  Drug development of MET inhibitors: targeting oncogene addiction and expedience.

Authors:  Paolo M Comoglio; Silvia Giordano; Livio Trusolino
Journal:  Nat Rev Drug Discov       Date:  2008-06       Impact factor: 84.694

9.  Chromosomal alterations in lung metastases of colorectal carcinomas: associations with tissue specific tumor dissemination.

Authors:  Thomas Knösel; Karsten Schlüns; Manfred Dietel; Iver Petersen
Journal:  Clin Exp Metastasis       Date:  2006-02-11       Impact factor: 5.150

Review 10.  Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.

Authors:  Xiangdong Liu; Robert C Newton; Peggy A Scherle
Journal:  Trends Mol Med       Date:  2009-12-22       Impact factor: 11.951

View more
  19 in total

Review 1.  Genomic diversity of colorectal cancer: Changing landscape and emerging targets.

Authors:  Daniel H Ahn; Kristen K Ciombor; Sameh Mikhail; Tanios Bekaii-Saab
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

2.  Pattern and Dynamics of Distant Metastases in Metastatic Colorectal Cancer.

Authors:  Julian Walter Holch; Maximilian Demmer; Charlotte Lamersdorf; Marlies Michl; Christoph Schulz; Jobst Christian von Einem; Dominik Paul Modest; Volker Heinemann
Journal:  Visc Med       Date:  2017-02-07

3.  NEAT1 regulates pancreatic cancer cell growth, invasion and migration though mircroRNA-335-5p/c-met axis.

Authors:  Jia Cao; Yi Zhang; Jiachun Yang; Sijia He; Mingming Li; Shiyan Yan; Ying Chen; Chunying Qu; Leiming Xu
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

Review 4.  Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Authors:  Conor A Bradley; Manuel Salto-Tellez; Pierre Laurent-Puig; Alberto Bardelli; Christian Rolfo; Josep Tabernero; Hajrah A Khawaja; Mark Lawler; Patrick G Johnston; Sandra Van Schaeybroeck
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

5.  c-MET immunohistochemical expression in sporadic and inflammatory bowel disease associated lesions.

Authors:  Grant Halliday; Ross J Porter; Catherine J Black; Mark J Arends; Shahida Din
Journal:  World J Gastroenterol       Date:  2022-04-07       Impact factor: 5.374

6.  Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.

Authors:  Avital Lev; Safoora Deihimi; Elena Shagisultanova; Joanne Xiu; Amriti R Lulla; David T Dicker; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2017-09-08       Impact factor: 4.742

7.  Transcriptomic landscape of early age onset of colorectal cancer identifies novel genes and pathways in Indian CRC patients.

Authors:  Manish Pratap Singh; Sandhya Rai; Nand K Singh; Sameer Srivastava
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

8.  miR-146a Polymorphism (rs2910164) Predicts Colorectal Cancer Patients' Susceptibility to Liver Metastasis.

Authors:  Tomohiro Iguchi; Sho Nambara; Takaaki Masuda; Hisateru Komatsu; Masami Ueda; Shinya Kidogami; Yushi Ogawa; Qingjiang Hu; Kuniaki Sato; Tomoko Saito; Hidenari Hirata; Shotaro Sakimura; Ryutaro Uchi; Naoki Hayashi; Shuhei Ito; Hidetoshi Eguchi; Keishi Sugimachi; Yoshihiko Maehara; Koshi Mimori
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

Review 9.  Targeting MET Dysregulation in Cancer.

Authors:  Gonzalo Recondo; Jianwei Che; Pasi A Jänne; Mark M Awad
Journal:  Cancer Discov       Date:  2020-06-12       Impact factor: 38.272

10.  A five-gene based risk score with high prognostic value in colorectal cancer.

Authors:  Yida Pan; Hongyang Zhang; Mingming Zhang; Jie Zhu; Jianghong Yu; Bangting Wang; Jigang Qiu; Jun Zhang
Journal:  Oncol Lett       Date:  2017-09-28       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.